Sargent Bickham Lagudis’s Bristol-Myers Squibb BMY Stock Holding History

Sargent Bickham Lagudis’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.44M	Sell	33,843 -1,024	-3%	-$77.2K	0.2%	95
2022 Q3	$2.48M	Sell	34,867 -2,487	-7%	-$180K	0.22%	89
2022 Q2	$2.88M	Buy	37,354 +2,527	+7%	+$192K	0.25%	93
2022 Q1	$2.54M	Sell	34,827 -9,464	-21%	-$635K	0.2%	96
2021 Q4	$2.76M	Sell	44,291 -25,027	-36%	-$1.47M	0.21%	93
2021 Q3	$4.1M	Buy	69,318 +982	+1%	+$64.7K	0.33%	67
2021 Q2	$4.57M	Buy	68,336 +2,140	+3%	+$140K	0.37%	60
2021 Q1	$4.18M	Buy	66,196 +4,346	+7%	+$270K	0.37%	61
2020 Q4	$3.84M	Buy	61,850 +1,280	+2%	+$78.7K	0.35%	64
2020 Q3	$3.65M	Buy	60,570 +5,379	+10%	+$324K	0.37%	60
2020 Q2	$3.25M	Buy	55,191 +36,563	+196%	+$2.19M	0.35%	65
2020 Q1	$1.04M	Sell	18,628 -787	-4%	-$48.1K	0.13%	114
2019 Q4	$1.25M	Buy	19,415 +1,194	+7%	+$68.4K	0.14%	109
2019 Q3	$924K	Buy	18,221 +125	+0.7%	+$5.88K	0.11%	115
2019 Q2	$821K	Buy	18,096 +3	+0%	+$140	0.1%	122
2019 Q1	$863K	Sell	18,093 -191	-1%	-$9.51K	0.1%	125
2018 Q4	$950K	Buy	18,284 +278	+2%	+$14.9K	0.12%	112
2018 Q3	$1.12M	Sell	18,006 -570	-3%	-$33.8K	0.13%	113
2018 Q2	$1.03M	Sell	18,576 -795	-4%	-$42.9K	0.13%	113
2018 Q1	$1.23M	Sell	19,371 -325	-2%	-$20.9K	0.15%	100
2017 Q4	$1.21M	Buy	19,696 +564	+3%	+$35.3K	0.14%	115
2017 Q3	$1.22M	Buy	19,132 +316	+2%	+$18.5K	0.15%	116
2017 Q2	$1.05M	Sell	18,816 -116	-0.6%	-$6.31K	0.13%	118
2017 Q1	$1.03M	Sell	18,932 -1,484	-7%	-$81.4K	0.13%	122
2016 Q4	$1.19M	Sell	20,416 -614	-3%	-$33.6K	0.18%	109
2016 Q3	$1.13K	Sell	21,030 -494	-2%	-$31.7K	0.17%	108
2016 Q2	$1.58M	Sell	21,524 -361	-2%	-$25.5K	0.25%	93
2016 Q1	$1.4M	Buy	+21,885	New	+$1.38M	0.23%	96

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Sargent Bickham Lagudis's BMY Position: Q4 2022 in Review

Sargent Bickham Lagudis reduced its Bristol-Myers Squibb (BMY) stake by 2.9% in Q4 2022, selling an estimated $77.2K and leaving 33,843 shares worth $2.44M. The position accounts for 0.2% of the portfolio, ranked #95.

Sargent Bickham Lagudis first reported a position in BMY in Q1 2016 and has held it in 28 quarters since. The position peaked at $4.57M in Q2 2021. 2,600 funds tracked by Wall St. Rank hold BMY as of Q4 2022.

Sargent Bickham Lagudis held 33,843 shares of Bristol-Myers Squibb worth $2.44M as of Q4 2022.
Sargent Bickham Lagudis sold 1,024 Bristol-Myers Squibb shares in Q4 2022, an estimated $77.2K.
Bristol-Myers Squibb made up 0.2% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #95 holding.
Sargent Bickham Lagudis first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 28 quarters since.
Sargent Bickham Lagudis's Bristol-Myers Squibb position peaked at $4.57M in Q2 2021.
2,600 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.